固定科研人员/Faculty

吴婷/Ting Wu

发布时间:2015/7/22 浏览量:945

吴婷 博士 教授 博士生导师

1994年毕业于上海医科大学药学院;2000年毕业于复旦大学药学院(原上海医科大学药学院),获博士学位。2003年1月起进入厦门大学。主要研究方向为疫苗临床试验和传染病的流行病学研究,目前做为国家传染病诊断试剂与疫苗工程技术研究中心“临床试验与流行病学研究”方向的组长开展人乳头瘤病毒(HPV)16/18型双价疫苗和HPV6/11双价疫苗的I-III期临床研究及相关流行病学研究。曾作为主要研究人员之一完成国家一类新药戊型肝炎病毒重组疫苗III期临床试验,目前仍承担数个重组戊肝疫苗的上市后临床研究项目。2010年受邀担任欧盟第7框架“疾病控制工具”(DISCONTOOLS - EU FP7)项目中食物源性戊型肝炎病毒专家组成员。作为主要研究人员主持或参与多项国家传染病重大科技专项、国家863项目、福建省科技重大专项等多个项目,与约翰霍普金斯大学、英国康沃尔医院、中国医学科学院肿瘤医院及国内多个省市级CDC、妇幼保健医院开展广泛的科研合作。

从事或正在承担的研究项目及所负责任:

l  863项目“ORF7基因敲除的减毒水痘活疫苗等几种新疫苗的研发(课题编号:2012AA02A408)”中任务“重组人乳头瘤病毒(HPV)16/18型双价疫苗的I/II/III期临床试验”的负责人

l  重大新药创制“重组戊型肝炎疫苗IV期临床试验(课题编号:2013ZX09101017)”主要执行人

l  863项目诊断试剂关键性原辅材料的研制(课题编号:2011AA02A114):项目负责人

l  艾滋病和病毒性肝炎等重大传染病防治项目“乙型病毒性肝炎免疫预防新策略研究”(2012.1-2015.12,课题编号: 2012ZX10002001):为子课题五中任务“HBsAg阳性人群的长期转归研究”(任务编号:2012ZX10002001-005-003)的任务负责人,

l  863重大项目(2007-2010):“重组戊型肝炎疫苗三期临床研究”(2006AA02A209),主要参加者,已结题。该课题完成了戊肝疫苗的III期临床研究,结果发表于《Lancet》。课题执行团队被评为“十一五规划国家科技计划优秀执行团队”, 本项目参展“十一五”国家重大科技成果展。

发明专利:

l 吴婷,伍小路,罗文新,张军,夏宁邵. 用于免疫或制备单克隆抗体的方法和组合物. 中国发明专利申请号:200610081554.4,授权日:2012.6

5年代表论文:

[1] Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J*, Xia NS*.  Safety of hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology, 2012, 55(6): 2038.(IF:11.665).

[2] Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z, Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine, 2015. (共通讯作者) (IF:3.624)

[3] Wu T#, Hu YM#*, Li J#, Chu K, Huang SJ, Zhao H, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW, Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity and safety of an E. coli–produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial. Vaccine, 2015, 33: 3940–3946. (共第一作者) (IF:3.624)

[4] Wu T*, Huang SJ, Zhu FC, Zhang XF, Ai X, Yan Q, Wang ZZ, Yang CL, Jiang HM, Liu XH, Guo M, Du HL, Ng MH, Zhang J, Xia NS.  Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. Human Vaccines & Immunotherapeutics, 2013, 9(11): 2474-9 (IF:2.131, 通讯作者)

[5] Li SW, Zhao QJ, Chen S, Wu T*, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. Human Vaccines & Immunotherapeutics, 2015, 11(4): 908--914.(综述,IF: 2.131)

[6] Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao QJ*. Hepatitis E vaccine development, A 14 year odyssey. Human Vaccines & Immunotherapeutics, 2012, 8: 823-827.(综述,IF: 2.131)

[7] Wu T, Zhang J, Xia NS*. Rationally respond to post-vaccination adverse events. Sci China Life Sc, 2014, 57 (5): 557–560. (综述,IF:2.02)

[8] Zhao H, Lin ZJ, Huang SJ, Li J, Liu XH, Guo M, Zhang J, Xia NS, Pan HR*, Wu T*, Li CG*. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Human Vaccines & Immunotherapeutics, 2014, 10 (3):740-6(IF: 2.131, 共通讯作者)

[9] Zhang J*, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. New Engl J Med, 2015, 372(10): 914-922. (IF 54.42)

[10]Wen GP, Tang ZM, Yang F, Zhang K, Ji WF, Cai W, Huang SJ, Wu T, Zhang J, Zheng ZZ*, Xia NS*. A valuable antigen detection method for diagnosis of acute hepatitis e. J Clin Microbiol. 2015, 53(3): 782-8. (IF)

[11] Zhu FC, Huang SJ, Wu T, Zhang XF, Wang ZZ, Ai X, Yan Q, Yang CL, Cai JP, Jiang HM, Wang YJ, Ng MH, Zhang J*, Xia NS. Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China. PLoS ONE, 2014, 9(1): e87154. doi: 10.1371/journal.pone.0087154(IF:4.411)

[12] Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ, Yang CL, Cai JP, Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, Zhang J*, Xia NS. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. Human Vaccines & Immunotherapeutics, 2014, 10(2): 1–7.(IF: 2.131)

[13] Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, yan Q, Yang CL, Jiang HM, Huang HJ, Xian YL, Shih JW, Ng MH, Li YM, Wang JZ*, Zhu FC*, Xia NS*. Protection against hepatitis E virus infection by naturally acquired and vaccine induced immunity. Clin Microbiol Infect. 2014; 20: O397–O405(IF:4.54)

[14] Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS*. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Rev Med Virol, 2012, 22(5): 339-349. doi: 10.1002/rmv.1719.(综述,IF:7.2)

[15] Zhao Q, Zhang J, Wu T, Li SW, Ng MH, Xia NS*, Shih JW*. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. J Gastroenterol. 2013 48(2):159-68. doi: 10.1007/s00535-012-0701-1. (综述,IF:4.16)

[16] Zhang J, Shih JW*, Wu T, Li SW, Xia NS. Development of the hepatitis e vaccine: from bench to field. Semin Liver Dis. 2013 Feb; 33(1):79-88. (综述,IF: 7.05)

[17] Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS*.  Efficacy and Safety of a Recombinant Hepatitis E Vaccine in Healthy Adults: A Large-scale, Double-blind, Randomized, Placebo Controlled Phase III Clinical Trial. Lancet, 2010, 376: 895–902. (IF:33.633)

[18] 陈书,卫飞雪,吴婷*,夏宁邵. 器官移植病人戊型肝炎病毒慢性化感染及治疗. 病毒学报, 2015, 31(3): 293-298(综述)

[19] 吴婷,张军,夏宁邵*. 科学对待疫苗接种后不良事件. 中国科学C辑,2014,44(5): 515-519(综述)

[20] 张军,吴婷,夏宁邵. 戊型肝炎诊断、预防及治疗新进展, 传染病信息,2013,26(2):89-92 (综述)

Conference Report:

[1]  15th International Symposium on Viral Hepatitis and Liver Disease, ISVHLD2015, Berlin, Germany, 2015.06. Vaccination Against Hepatitis E.

[2] Meeting on Appropriate Clinical Endpoints for 2nd Generation HPV Vaccine Trials, Geneva, Switzerland, 2014.11. The Progress in Development of Xiamen HPV Vaccine.

[3] Global advisory committee on vaccine safety, 2014.06. Development of Hecolin.

[4] Asian-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2014, Beijing China, 2014.04. Correlation between ELISA and Pseudovirion-based Neutralisation Assay for Detecting Antibodies against Human Papillomavirus Acquired by Natural Infection or by Vaccination.

[5] Meeting on Appropriate Clinical Endpoints for 2nd Generation HPV Vaccine Trials, Geneva, Switzerland, 2013.11. The Development of Xiamen HPV Vaccine.

[6] The DISCONTOOLS hepatitis E virus expert group meeting, Utrecht, Netherland, 2011.05. Development of a Hepatitis E Vaccine.

[7] MICROCON 2010, XXXIV National Conference of Indian Association of Medical Microbiologists, Kolkata, India, 2010.11. Hepatitis E- a Neglected Disease.

[8] 11th Annual General Meeting & Conference of DCVMN,  Hyderabad, India ,  2010.09.  Hepatitis E Vaccine (Hecolin)-Not a Moment Too Soon. .

微信扫一扫
关注国重室公众号